Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JJH201601 liposome is an investigational liposomal formulation of a novel docetaxel derivative (JJH201601) developed by Jiangsu Jibeier Pharmaceutical. Designed to improve the therapeutic index of docetaxel, JJH201601 acts as a tubulin inhibitor that stabilizes microtubules and disrupts cell cycle progression. The liposomal delivery system is engineered to enhance tumor targeting, reduce systemic toxicities, and potentially overcome multidrug resistance mechanisms such as P-glycoprotein-mediated efflux. It is currently undergoing Phase Ib/IIa clinical evaluation for the treatment of advanced solid tumors, including pancreatic cancer, biliary tract cancer, and hepatocellular carcinoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JJH201601 liposome.